Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firi-cel in Relapsed/Refractory Large B-Cell Lymphoma
NCT05972720Phase 2Terminated
- Sponsor
- CARGO Therapeutics
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of firicabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by CARGO Therapeutics. Started Aug 2023; status: terminated.
02
Drugs
firicabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05972720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972720.